A national preexposure prophylaxis (PrEP) program would streamline access and improve HIV outcomes but unfortunately never came to pass because of a lack of funding, according to Jeremiah Johnson, executive director, PrEP4All.
A national preexposure prophylaxis (PrEP) program in the United States is something of interest for Jeremiah Johnson, executive director, PrEP4All. However, the funding for such a program remains limited.
“What we have wanted to do is pull together a coordinated, simultaneous program that addresses the major barriers to PrEP access that we hear about repeatedly from community members, one being the complexity of cost and coverage,” Johnson said in an interview with Managed Healthcare Executive. “We did see the Biden administration call for such a program three years in a row and their budget request to Congress. We've not seen that request continue with the Trump administration.”
Jeremiah Johnson
Johnson said that his organization was successful in getting the Centers for Disease Control and Prevention (CDC) to study HIV prevention strategies at five pilot sites across the United States. This was the first time CDC funds were allowed to go directly toward paying for antiretrovirals of any kind.
“The big challenge we're seeing right now is that the Trump administration and its budget request to Congress for FY 26 have all but eliminated the division of HIV prevention at CDC, while they have maintained in their proposal some funding for the Ending the HIV Epidemic Initiative,” Johnson said.
The initiative was started by President Trump in 2019, during his first term.
Johnson likened the defunding to removing the house foundation but leaving the roof.
“You're not going to be able to build any sort of 'ending the epidemic' response if you don't have basic surveillance testing, not to mention all of the essential PrEP services that you see there,” Johnson said.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More